Single-agent temozolomide as salvage therapy in heavily pretreated metastatic sarcoma patients.

Journal

Journal of cancer research and therapeutics

ISSN: 1998-4138

Titre abrégé: J Cancer Res Ther

Pays: India

ID NLM: 101249598

Informations de publication

Date de publication:
01 Jan 2024

Historique:

received: 31 08 2022

accepted: 03 09 2022

medline: 30 3 2024

pubmed: 30 3 2024

entrez: 30 3 2024

Statut: ppublish

Résumé

Treatment options for patients with metastatic sarcoma are limited. The goal of this study was to investigate the effectiveness of temozolomide in pretreated patients with soft tissue sarcoma. We recorded the pathological, clinical, and treatment data of the patients with metastatic soft tissue sarcoma retrospectively. We evaluated the efficacy and side effects of temozolomide in this patient group. This study involved 16 patients. The average age was detected as 48 (21-73) years. Six (37.5%) patients had de-novo metastatic disease at diagnosis. Primary of tumors had originated from intra-abdominal (43.7%), extremity (31.3%), head-and-neck (12.5%), and intrathoracic (12.5%) regions. The patients previously had received at least two different chemotherapy regimens (75%), pazopanib (50%) and palliative radiotherapy (31.3%). Temozolomide-related median progression-free survival time was found as 3.5 (95% CI, 2.6-4.3) months. One patient (6.3%) had a partial response, while four patients (25%) had stable disease. Nine individuals (56.3%) had grade 1-2 adverse events, while one patient (6.3%) had grade 3-4 adverse events. We observed that temozolomide was well tolerated but had limited efficacy in the treatment of metastatic sarcoma patients. In patients with extensively pretreated soft tissue sarcoma, temozolomide may be considered a therapeutic option as a single-agent.

Sections du résumé

BACKGROUND BACKGROUND

Treatment options for patients with metastatic sarcoma are limited. The goal of this study was to investigate the effectiveness of temozolomide in pretreated patients with soft tissue sarcoma.

METHODS METHODS

We recorded the pathological, clinical, and treatment data of the patients with metastatic soft tissue sarcoma retrospectively. We evaluated the efficacy and side effects of temozolomide in this patient group.

RESULTS RESULTS

This study involved 16 patients. The average age was detected as 48 (21-73) years. Six (37.5%) patients had de-novo metastatic disease at diagnosis. Primary of tumors had originated from intra-abdominal (43.7%), extremity (31.3%), head-and-neck (12.5%), and intrathoracic (12.5%) regions. The patients previously had received at least two different chemotherapy regimens (75%), pazopanib (50%) and palliative radiotherapy (31.3%). Temozolomide-related median progression-free survival time was found as 3.5 (95% CI, 2.6-4.3) months. One patient (6.3%) had a partial response, while four patients (25%) had stable disease. Nine individuals (56.3%) had grade 1-2 adverse events, while one patient (6.3%) had grade 3-4 adverse events.

CONCLUSIONS CONCLUSIONS

We observed that temozolomide was well tolerated but had limited efficacy in the treatment of metastatic sarcoma patients. In patients with extensively pretreated soft tissue sarcoma, temozolomide may be considered a therapeutic option as a single-agent.

Identifiants

DOI: 10.4103/jcrt.jcrt_1827_22 PMID: 38554304

pubmed: 38554304

doi: 10.4103/jcrt.jcrt_1827_22

pii: 01363817-202420010-00014

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

93-97

Informations de copyright

Références

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33.

Lim J, Poulin NM, Nielsen TO. New strategies in sarcoma:Linking genomic and ımmunotherapy approaches to molecular subtype. Clin Cancer Res 2015;21:4753–9.

Lawrence W Jr, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 1987;205:349–59.

Burningham Z, Hashibe M, Spector L, Schiffman JD. The epidemiology of sarcoma. Clin Sarcoma Res 2012;2:14.

Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, et al. Monogenic and polygenic determinants of sarcoma risk:An international genetic study. Lancet Oncol 2016;17:1261–71.

Italiano A, Di Mauro I, Rapp J, Pierron G, Auger N, Alberti L, et al. Clinical effect of molecular methods in sarcoma diagnosis (GENSARC):A prospective, multicentre, observational study. Lancet Oncol 2016;17:532–8.

Lahat G, Tuvin D, Wei C, Anaya DA, Bekele BN, Lazar AJ, et al. New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol 2008;15:2739–48.

Frezza AM, Stacchiotti S, Gronchi A. Systemic treatment in advanced soft tissue sarcoma:What is standard, what is new. BMC Med 2017;15:109.

In GK, Hu JS, Tseng WW. Treatment of advanced, metastatic soft tissue sarcoma:Latest evidence and clinical considerations. Ther Adv Med Oncol 2017;9:533–50.

Tatar Z, Thivat E, Planchat E, Gimbergues P, Gadea E, Abrial C, et al. Temozolomide and unusual indications:Review of literature. Cancer Treat Rev 2013;39:125–35.

Woll PJ, Judson I, Lee SM, Rodenhuis S, Nielsen OS, Buesa JM, et al. Temozolomide in adult patients with advanced soft tissue sarcoma:A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1999;35:410–2.

Anderson S, Aghajanian C. Temozolomide in uterine leiomyosarcomas. Gynecol Oncol 2005;98:99–103.

Talbot SM, Keohan ML, Hesdorffer M, Orrico R, Bagiella E, Troxel AB, et al. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer 2003;98:1942–6.

Engert F, Schneider C, Weibeta LM, Probst M, Fulda S. PARP ınhibitors sensitize ewing sarcoma cells to temozolomide-ınduced apoptosis via the mitochondrial pathway. Mol Cancer Ther 2015;14:2818–30.

Blanchette PS, Lo A, Ng P, Razak A, Amir E, Hogg D, et al. Irinotecan and temozolomide in adults with recurrent sarcoma. J Solid Tumors 2015;5:105–11.

Iqbal N, Shukla NK, Deo SV, Agarwala S, Sharma DN, Sharma MC, et al. Prognostic factors affecting survival in metastatic soft tissue sarcoma:An analysis of 110 patients. Clin Transl Oncol 2016;18:310–6.

Lindner LH, Litiere S, Sleijfer S, Benson C, Italiano A, Kasper B, et al. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first line chemotherapy:An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Int J Cancer 2018;142:2610–20.

Kang S, Kim HS, Kim S, Kim W, Han I. Post-metastasis survival in extremity soft tissue sarcoma:A recursive partitioning analysis of prognostic factors. Eur J Cancer 2014;50:1649–56.